logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.

    • Androgen Receptor Inhibitor class drugs

    FiltersReset Filters
    5 results

    • bicalutamide

      (Bicalutamide)
      Golden State Medical Supply, Inc.
      Usage: Bicalutamide tablets are indicated for use in combination with a luteinizing hormone-releasing hormone (LHRH) analog to treat Stage D2 metastatic carcinoma of the prostate. The 150 mg dose is not approved for standalone use or with other treatments.

    • nilandron

      (Nilutamide)
      Concordia Pharmaceuticals Inc.
      Usage: NILANDRON tablets are indicated for use in combination with surgical castration to treat metastatic prostate cancer (Stage D2). Treatment should start on the same day or the day after surgical castration for optimal effectiveness.

    • nilutamide

      (Nilutamide)
      Prasco Laboratories
      Usage: Nilutamide tablets are indicated for use alongside surgical castration to treat metastatic prostate cancer (Stage D2). For optimal effectiveness, treatment with Nilutamide should start on the same day as or the day after the surgical procedure.

    • winlevi

      (Clascoterone)
      Sun Pharmaceutical Industries, Inc.
      Usage: WINLEVI (clascoterone) cream is indicated for the topical treatment of acne vulgaris in patients aged 12 years and older.

    • xtandi

      (enzalutamide)
      Astellas Pharma US, Inc.
      Usage: XTANDI® is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), metastatic castration-sensitive prostate cancer (mCSPC), and non-metastatic castration-sensitive prostate cancer (nmCSPC) experiencing high-risk biochemical recurrence (high-risk BCR).